Christian Wilson R Turalde1, Kevin Michael C Moalong2, Adrian I Espiritu3,4, Mario B Prado2. 1. Division of Adult Neurology, Department of Neurosciences, Philippine General Hospital, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Taft Avenue, Ermita, 1000, Manila, Philippines. crturalde@up.edu.ph. 2. Division of Adult Neurology, Department of Neurosciences, Philippine General Hospital, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Taft Avenue, Ermita, 1000, Manila, Philippines. 3. Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines. 4. Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada.
Abstract
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease. There is still no established cost-effective treatment that can improve functional status and survival of ALS patients. Perampanel, by inhibiting neuronal calcium ion influx and preventing dyslocalization of nuclear proteins, has the potential to ameliorate ALS neurodegeneration. OBJECTIVES: This study aims to determine the efficacy and safety of perampanel among ALS patients in terms of improvement in functional status using a review of relevant studies. METHODS: MedLine, Cochrane Central Register for Controlled Trials, Scopus, Embase, Literatura Latino-Americana e do Caribe em Ciências da Saúde, ClinicalTrials.gov website, and HERDIN databases were searched from inception to August 2021 for relevant studies. RESULTS: The search yielded 132 articles; 3 studies were included in the analysis. Pooled evidence shows that perampanel compared to placebo significantly improves cortical motor hyperexcitability but not the ALS functional rating scale-revised score. Perampanel is associated with adverse events such as aggression, somnolence, anger, and dysarthria. CONCLUSION: There is no sufficient evidence to support the role of perampanel in improving functional status of ALS patients. Although it can ameliorate motor cortical hyperexcitability, its clinical benefit has not yet been elucidated. Perampanel is not well tolerated among ALS patients as it is associated with adverse events such as aggression, somnolence, anger, and dysarthria. Further studies investigating the role of perampanel early in the ALS disease course, excluding ALS patients with frontotemporal lobe degeneration features and C9ORF72 repeat expansion, and using gradual drug titration schedule are needed to evaluate the potential benefit of perampanel in ALS.
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease. There is still no established cost-effective treatment that can improve functional status and survival of ALS patients. Perampanel, by inhibiting neuronal calcium ion influx and preventing dyslocalization of nuclear proteins, has the potential to ameliorate ALS neurodegeneration. OBJECTIVES: This study aims to determine the efficacy and safety of perampanel among ALS patients in terms of improvement in functional status using a review of relevant studies. METHODS: MedLine, Cochrane Central Register for Controlled Trials, Scopus, Embase, Literatura Latino-Americana e do Caribe em Ciências da Saúde, ClinicalTrials.gov website, and HERDIN databases were searched from inception to August 2021 for relevant studies. RESULTS: The search yielded 132 articles; 3 studies were included in the analysis. Pooled evidence shows that perampanel compared to placebo significantly improves cortical motor hyperexcitability but not the ALS functional rating scale-revised score. Perampanel is associated with adverse events such as aggression, somnolence, anger, and dysarthria. CONCLUSION: There is no sufficient evidence to support the role of perampanel in improving functional status of ALS patients. Although it can ameliorate motor cortical hyperexcitability, its clinical benefit has not yet been elucidated. Perampanel is not well tolerated among ALS patients as it is associated with adverse events such as aggression, somnolence, anger, and dysarthria. Further studies investigating the role of perampanel early in the ALS disease course, excluding ALS patients with frontotemporal lobe degeneration features and C9ORF72 repeat expansion, and using gradual drug titration schedule are needed to evaluate the potential benefit of perampanel in ALS.
Authors: Michael A van Es; Orla Hardiman; Adriano Chio; Ammar Al-Chalabi; R Jeroen Pasterkamp; Jan H Veldink; Leonard H van den Berg Journal: Lancet Date: 2017-05-25 Impact factor: 79.321
Authors: Dawn Dobson; Peter L B J Lucassen; Joyce J Miller; Arine M Vlieger; Philip Prescott; George Lewith Journal: Cochrane Database Syst Rev Date: 2012-12-12
Authors: A Chiò; G Logroscino; B J Traynor; J Collins; J C Simeone; L A Goldstein; L A White Journal: Neuroepidemiology Date: 2013-07-11 Impact factor: 3.282
Authors: Sabrina Paganoni; Suzanne Hendrix; Samuel P Dickson; Newman Knowlton; Eric A Macklin; James D Berry; Michael A Elliott; Samuel Maiser; Chafic Karam; James B Caress; Margaret Ayo Owegi; Adam Quick; James Wymer; Stephen A Goutman; Daragh Heitzman; Terry D Heiman-Patterson; Carlayne E Jackson; Colin Quinn; Jeffrey D Rothstein; Edward J Kasarskis; Jonathan Katz; Liberty Jenkins; Shafeeq Ladha; Timothy M Miller; Stephen N Scelsa; Tuan H Vu; Christina N Fournier; Jonathan D Glass; Kristin M Johnson; Andrea Swenson; Namita A Goyal; Gary L Pattee; Patricia L Andres; Suma Babu; Marianne Chase; Derek Dagostino; Meghan Hall; Gale Kittle; Matthew Eydinov; Michelle McGovern; Joseph Ostrow; Lindsay Pothier; Rebecca Randall; Jeremy M Shefner; Alexander V Sherman; Maria E St Pierre; Eric Tustison; Prasha Vigneswaran; Jason Walker; Hong Yu; James Chan; Janet Wittes; Zi-Fan Yu; Joshua Cohen; Justin Klee; Kent Leslie; Rudolph E Tanzi; Walter Gilbert; Patrick D Yeramian; David Schoenfeld; Merit E Cudkowicz Journal: Muscle Nerve Date: 2020-10-30 Impact factor: 3.217
Authors: Matthew C Kiernan; Steve Vucic; Kevin Talbot; Christopher J McDermott; Orla Hardiman; Jeremy M Shefner; Ammar Al-Chalabi; William Huynh; Merit Cudkowicz; Paul Talman; Leonard H Van den Berg; Thanuja Dharmadasa; Paul Wicks; Claire Reilly; Martin R Turner Journal: Nat Rev Neurol Date: 2020-12-18 Impact factor: 42.937
Authors: Anna M Blokhuis; Ewout J N Groen; Max Koppers; Leonard H van den Berg; R Jeroen Pasterkamp Journal: Acta Neuropathol Date: 2013-05-15 Impact factor: 17.088
Authors: Sabrina Paganoni; Eric A Macklin; Suzanne Hendrix; James D Berry; Michael A Elliott; Samuel Maiser; Chafic Karam; James B Caress; Margaret A Owegi; Adam Quick; James Wymer; Stephen A Goutman; Daragh Heitzman; Terry Heiman-Patterson; Carlayne E Jackson; Colin Quinn; Jeffrey D Rothstein; Edward J Kasarskis; Jonathan Katz; Liberty Jenkins; Shafeeq Ladha; Timothy M Miller; Stephen N Scelsa; Tuan H Vu; Christina N Fournier; Jonathan D Glass; Kristin M Johnson; Andrea Swenson; Namita A Goyal; Gary L Pattee; Patricia L Andres; Suma Babu; Marianne Chase; Derek Dagostino; Samuel P Dickson; Noel Ellison; Meghan Hall; Kent Hendrix; Gale Kittle; Michelle McGovern; Joseph Ostrow; Lindsay Pothier; Rebecca Randall; Jeremy M Shefner; Alexander V Sherman; Eric Tustison; Prasha Vigneswaran; Jason Walker; Hong Yu; James Chan; Janet Wittes; Joshua Cohen; Justin Klee; Kent Leslie; Rudolph E Tanzi; Walter Gilbert; Patrick D Yeramian; David Schoenfeld; Merit E Cudkowicz Journal: N Engl J Med Date: 2020-09-03 Impact factor: 176.079